WAVEMAN · COMPANY

OLN · Olin Corp

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

OLN

Name: OLIN Corp (OLN) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

OLIN Corp

PHARMA & BIOTECH · CHEMICALS & ALLIED PRODUCTS · CIK 0000074303

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

216

13F, latest reported quarter

REVENUE GROWTH

+3.7%

XBRL, annual

NET MARGIN

-1.5%

CONVERSIONS · 180D

codes C/M, not in net · no price filed

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

216 funds added or opened last quarter

more than 89% of Pharma & Biotech

REVENUE

+3.7% year over year

more than 51% of Pharma & Biotech

MARGIN

-1.5% net margin

more than 64% of Pharma & Biotech

BUYBACKS

$50.5M repurchased, FY to 2025-12-31

more than 57% of Pharma & Biotech

SHORT

10.8% of shares outstanding short · 3.7 days to cover · settled 2026-07-31

more than 80% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

216 funds added or opened positions in the latest 13F quarter, of 415 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -23.1%

-23.1%12M

INSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 216 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for OLIN Corp in the period covered. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

Carter Deon

VP & President CAPV

SELL

2026-02-25

6,500.0

$154.2K

Castle Angela M

VP & Chief Legal Officer

SELL

2026-02-24

2,379.26

$57.7K

Sumner R Nichole

VP & Controller

SELL

2026-02-03

4,750.0

$106.8K

Slater Todd A

VP & CFO

SELL

2026-02-03

92,250.0

$2.1M

VERMILLION TERESA M

VP & Treasurer

SELL

2025-11-26

4,500.0

$93.9K

78 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 73 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC

16,021,214.0 sh

$317.5M

BlackRock, Inc.

11,984,254.0 sh

$237.5M

DIMENSIONAL FUND ADVISORS LP

6,166,477.0 sh

$122.2M

AQR CAPITAL MANAGEMENT LLC

5,510,335.0 sh

$109.2M

VANGUARD PORTFOLIO MANAGEMENT LLC

5,447,478.0 sh

$108.0M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

HW Opportunities MP Fund

$7.2M POSITION · AS OF 2026-03-31

9.5%

Hotchkis and Wiley Small Cap Value Fund

$32.9M POSITION · AS OF 2026-03-31

5.0%

Hotchkis and Wiley Value Opportunities Fund

$30.5M POSITION · AS OF 2026-03-31

3.8%

The Acquirers Fund

$1.2M POSITION · AS OF 2026-04-30

3.7%

First Trust Materials AlphaDEX Fund

$11.7M POSITION · AS OF 2026-04-30

3.0%

Hotchkis and Wiley Mid-Cap Value Fund

$12.0M POSITION · AS OF 2026-03-31

3.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Government contracts

USASpending.gov · total award ceilings over the contract's life, including awards won through subsidiaries — not annual revenue

Department Of Defense

THE PURPOSE OF THIS DELIVERY ORDER IS TO AWARD THE XM1201 ONE-WAY LUMINESCENT (OWL) TRACER MANUFACTU · 2021-03-29

$356.4M

FEDERAL AWARDS ≥ $25M IN THE LAST 90 DAYS · MATCHED VIA SAM.GOV PARENT REGISTRY

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$6.8B	$6.5B	$6.8B	$9.4B
GROSS PROFIT	$501.5M	$737.5M	$1.2B	$2.2B
OPERATING INCOME	$5.3M	$296.5M	$712.1M	$1.8B
NET INCOME	$-101.1M	$105.0M	$452.0M	$1.3B
EPS (DILUTED)	-0.88	0.91	3.57	8.94
OPERATING CASH FLOW	$474.2M	$503.2M	$974.3M	$1.9B
CASH	$167.6M	$175.6M	$170.3M	$194.0M
LONG-TERM DEBT	$2.7B	$2.7B	$2.6B	$2.6B
BUYBACKS	$50.5M	$300.3M	$711.3M	$1.4B
DIVIDENDS PAID	$91.6M	$94.2M	$101.0M	$116.2M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE